|
|
||||||||
-Facilitated Rejection of Murine B16 Melanomas1


Institutes of
*
Medical Microbiology and
Pathology, University of Ulm, Ulm, Germany
The murine melanoma cell line B16.F10 (H-2b) was
used to study specific T cell responses that reject tumors. Stable B16
transfectants were established that express viral Ags, either the
hepatitis B surface Ag (HBsAg) or the large tumor Ag (T-Ag) of SV40.
B16 cells and their transfected sublines were
CD40+CD44+ but expressed no (or low levels of
the) costimulator molecules CD154 (CD40L), CD48, CD54, CD80, and CD86.
Surface expression of MHC class I (Kb, Db) and
class II (I-Ab) molecules by B16 cells was low, but
strikingly up-regulated by IFN-
. CD95 (Fas) and CD95 ligand (CD95L
(FasL)) were "spontaneously" expressed by B16 cells growing in
vitro in serum-free medium; these markers were strikingly up-regulated
by IFN-
. B16 cells coexpressing CD95 and CD95L were irreversibly
programed for apoptosis. In vitro, noninduced B16 transfectants
stimulated a specific IFN-
release response, but no cytolytic
response (in a 4-h assay) in MHC class I-restricted CTL; in contrast,
IFN-
-induced B16 targets were efficiently and specifically lysed by
CTL. In vivo, B16 transfectants were specifically rejected by
DNA-vaccinated syngeneic hosts through a T-dependent immune effector
mechanism. The tumors showed evidence of massive apoptosis in vivo
during the rejection process. The data suggest that CTL-derived IFN-
enhances an intrinsic suicide mechanism of these tumor cells in
addition to facilitating lytic interactions of effectors with tumor
targets.
This article has been cited by other articles:
![]() |
C. A. Klebanoff, Z. Yu, L. N. Hwang, D. C. Palmer, L. Gattinoni, and N. P. Restifo Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination Blood, August 27, 2009; 114(9): 1776 - 1783. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Liu, Y. Peng, M. Mi, J. Guevara-Patino, D. H. Munn, N. Fu, and Y. He Lentivector Immunization Stimulates Potent CD8 T Cell Responses against Melanoma Self-Antigen Tyrosinase-Related Protein 1 and Generates Antitumor Immunity in Mice J. Immunol., May 15, 2009; 182(10): 5960 - 5969. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Wang, W. Asavaroengchai, B. Yong Yeap, M.-G. Wang, S. Wang, M. Sykes, and Y.-G. Yang Paradoxical effects of IFN-{gamma} in graft-versus-host disease reflect promotion of lymphohematopoietic graft-versus-host reactions and inhibition of epithelial tissue injury Blood, April 9, 2009; 113(15): 3612 - 3619. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Wang, H. Wei, R. Zhang, S. Hou, B. Li, W. Qian, D. Zhang, G. Kou, J. Dai, and Y. Guo Genetically Targeted T Cells Eradicate Established Breast Cancer in Syngeneic Mice Clin. Cancer Res., February 1, 2009; 15(3): 943 - 950. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Muranski, A. Boni, P. A. Antony, L. Cassard, K. R. Irvine, A. Kaiser, C. M. Paulos, D. C. Palmer, C. E. Touloukian, K. Ptak, et al. Tumor-specific Th17-polarized cells eradicate large established melanoma Blood, July 15, 2008; 112(2): 362 - 373. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Stoitzner, L. K. Green, J. Y. Jung, K. M. Price, C. H. Tripp, B. Malissen, A. Kissenpfennig, I. F. Hermans, and F. Ronchese Tumor Immunotherapy by Epicutaneous Immunization Requires Langerhans Cells J. Immunol., February 1, 2008; 180(3): 1991 - 1998. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. H.D. Hallett, E. Ames, M. Motarjemi, I. Barao, A. Shanker, D. L. Tamang, T. J. Sayers, D. Hudig, and W. J. Murphy Sensitization of Tumor Cells to NK Cell-Mediated Killing by Proteasome Inhibition J. Immunol., January 1, 2008; 180(1): 163 - 170. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Pivarcsi, A. Muller, A. Hippe, J. Rieker, A. van Lierop, M. Steinhoff, S. Seeliger, R. Kubitza, U. Pippirs, S. Meller, et al. Tumor immune escape by the loss of homeostatic chemokine expression PNAS, November 27, 2007; 104(48): 19055 - 19060. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. W. Overwijk, K. E. de Visser, F. H. Tirion, L. A. de Jong, T. W. H. Pols, Y. U. van der Velden, J. G. van den Boorn, A. M. Keller, W. A. Buurman, M. R. Theoret, et al. Immunological and Antitumor Effects of IL-23 as a Cancer Vaccine Adjuvant J. Immunol., May 1, 2006; 176(9): 5213 - 5222. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Motomura, S. Senju, T. Nakatsura, H. Matsuyoshi, S. Hirata, M. Monji, H. Komori, D. Fukuma, H. Baba, and Y. Nishimura Embryonic Stem Cell-Derived Dendritic Cells Expressing Glypican-3, a Recently Identified Oncofetal Antigen, Induce Protective Immunity against Highly Metastatic Mouse Melanoma, B16-F10 Cancer Res., February 15, 2006; 66(4): 2414 - 2422. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Hokey, A. T. Larregina, G. Erdos, S. C. Watkins, and L. D. Falo Jr. Tumor Cell Loaded Type-1 Polarized Dendritic Cells Induce Th1-Mediated Tumor Immunity Cancer Res., November 1, 2005; 65(21): 10059 - 10067. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. He, J. Zhang, Z. Mi, P. Robbins, and L. D. Falo Jr Immunization with Lentiviral Vector-Transduced Dendritic Cells Induces Strong and Long-Lasting T Cell Responses and Therapeutic Immunity J. Immunol., March 15, 2005; 174(6): 3808 - 3817. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. C. Palmer, S. Balasubramaniam, K.-i. Hanada, C. Wrzesinski, Z. Yu, S. Farid, M. R. Theoret, L. N. Hwang, C. A. Klebanoff, L. Gattinoni, et al. Vaccine-Stimulated, Adoptively Transferred CD8+ T Cells Traffic Indiscriminately and Ubiquitously while Mediating Specific Tumor Destruction J. Immunol., December 15, 2004; 173(12): 7209 - 7216. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Radhakrishnan, L. T. Nguyen, B. Ciric, D. Flies, V. P. V. Keulen, K. Tamada, L. Chen, M. Rodriguez, and L. R. Pease Immunotherapeutic Potential of B7-DC (PD-L2) Cross-Linking Antibody In Conferring Antitumor Immunity Cancer Res., July 15, 2004; 64(14): 4965 - 4972. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Puliaev, P. Nguyen, F. D. Finkelman, and C. S. Via Differential Requirement for IFN-{gamma} in CTL Maturation in Acute Murine Graft-versus-Host Disease J. Immunol., July 15, 2004; 173(2): 910 - 919. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Lengagne, F.-A. Le Gal, M. Garcette, L. Fiette, P. Ave, M. Kato, J.-P. Briand, C. Massot, I. Nakashima, L. Renia, et al. Spontaneous Vitiligo in an Animal Model for Human Melanoma: Role of Tumor-specific CD8+ T Cells Cancer Res., February 15, 2004; 64(4): 1496 - 1501. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Matsuyoshi, S. Senju, S. Hirata, Y. Yoshitake, Y. Uemura, and Y. Nishimura Enhanced Priming of Antigen-Specific CTLs In Vivo by Embryonic Stem Cell-Derived Dendritic Cells Expressing Chemokine Along with Antigenic Protein: Application to Antitumor Vaccination J. Immunol., January 15, 2004; 172(2): 776 - 786. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Goldszmid, J. Idoyaga, A. I. Bravo, R. Steinman, J. Mordoh, and R. Wainstok Dendritic Cells Charged with Apoptotic Tumor Cells Induce Long-Lived Protective CD4+ and CD8+ T Cell Immunity against B16 Melanoma J. Immunol., December 1, 2003; 171(11): 5940 - 5947. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Chapdelaine, D. K. Smith, J. A. Pedras-Vasconcelos, L. Krishnan, and S. Sad Increased CD8+ T Cell Memory to Concurrent Infection at the Expense of Increased Erosion of Pre-existing Memory: The Paradoxical Role of IL-15 J. Immunol., November 15, 2003; 171(10): 5454 - 5460. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Murakami, A. R. Cardones, S. E. Finkelstein, N. P. Restifo, B. A. Klaunberg, F. O. Nestle, S. S. Castillo, P. A. Dennis, and S. T. Hwang Immune Evasion by Murine Melanoma Mediated through CC Chemokine Receptor-10 J. Exp. Med., November 3, 2003; 198(9): 1337 - 1347. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-T. Rubio, Y.-M. Kim, T. Sachs, M. Mapara, G. Zhao, and M. Sykes Antitumor effect of donor marrow graft rejection induced by recipient leukocyte infusions in mixed chimeras prepared with nonmyeloablative conditioning: critical role for recipient-derived IFN-{gamma} Blood, September 15, 2003; 102(6): 2300 - 2307. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Krishnan, S. Sad, G. B. Patel, and G. D. Sprott Archaeosomes Induce Enhanced Cytotoxic T Lymphocyte Responses to Entrapped Soluble Protein in the Absence of Interleukin 12 and Protect against Tumor Challenge Cancer Res., May 15, 2003; 63(10): 2526 - 2534. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Schuler and T. Blankenstein Cutting Edge: CD8+ Effector T Cells Reject Tumors by Direct Antigen Recognition but Indirect Action on Host Cells J. Immunol., May 1, 2003; 170(9): 4427 - 4431. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Y. Chiang, M. Henson, and I. Stroynowski Correction of Defects Responsible for Impaired Qa-2 Class Ib MHC Expression on Melanoma Cells Protects Mice from Tumor Growth J. Immunol., May 1, 2003; 170(9): 4515 - 4523. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. H. Poehlein, H.-M. Hu, J. Yamada, I. Assmann, W. G. Alvord, W. J. Urba, and B. A. Fox TNF Plays an Essential Role in Tumor Regression after Adoptive Transfer of Perforin/IFN-{gamma} Double Knockout Effector T Cells J. Immunol., February 15, 2003; 170(4): 2004 - 2013. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. M. Haynes, J. A. Trapani, M. W. L. Teng, J. T. Jackson, L. Cerruti, S. M. Jane, M. H. Kershaw, M. J. Smyth, and P. K. Darcy Rejection of Syngeneic Colon Carcinoma by CTLs Expressing Single-Chain Antibody Receptors Codelivering CD28 Costimulation J. Immunol., November 15, 2002; 169(10): 5780 - 5786. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. S. Lehmann, L. Terracciano, I. Carena, C. Baeriswyl, J. Drewe, L. Tornillo, G. De Libero, and C. Beglinger In situ correlation of cytokine secretion and apoptosis in Helicobacter pylori-associated gastritis Am J Physiol Gastrointest Liver Physiol, August 1, 2002; 283(2): G481 - G488. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Dudani, Y. Chapdelaine, H. v. Faassen, D. K. Smith, H. Shen, L. Krishnan, and S. Sad Multiple Mechanisms Compensate to Enhance Tumor-Protective CD8+ T Cell Response in the Long-Term Despite Poor CD8+ T Cell Priming Initially: Comparison Between an Acute Versus a Chronic Intracellular Bacterium Expressing a Model Antigen J. Immunol., June 1, 2002; 168(11): 5737 - 5745. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-G. Yang, J. Qi, M.-G. Wang, and M. Sykes Donor-derived interferon gamma separates graft-versus-leukemia effects and graft-versus-host disease induced by donor CD8 T cells Blood, May 13, 2002; 99(11): 4207 - 4215. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Huang, F. Li, J. R. Gordon, and J. Xiang Synergistic Enhancement of Antitumor Immunity with Adoptively Transferred Tumor-specific CD4+ and CD8+ T Cells and Intratumoral Lymphotactin Transgene Expression Cancer Res., April 1, 2002; 62(7): 2043 - 2051. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Seki, A. D. Brooks, C. R. D. Carter, T. C. Back, E. M. Parsoneault, M. J. Smyth, R. H. Wiltrout, and T. J. Sayers Tumor-Specific CTL Kill Murine Renal Cancer Cells Using Both Perforin and Fas Ligand-Mediated Lysis In Vitro, But Cause Tumor Regression In Vivo in the Absence of Perforin J. Immunol., April 1, 2002; 168(7): 3484 - 3492. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Teshima, C. Liu, K. P. Lowler, G. Dranoff, and J. L. M. Ferrara Donor Leukocyte Infusion from Immunized Donors Increases Tumor Vaccine Efficacy after Allogeneic Bone Marrow Transplantation Cancer Res., February 1, 2002; 62(3): 796 - 800. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Winter, H.-M. Hu, K. McClain, W. J. Urba, and B. A. Fox Immunotherapy of Melanoma: A Dichotomy in the Requirement for IFN-{{gamma}} in Vaccine-Induced Antitumor Immunity Versus Adoptive Immunotherapy J. Immunol., June 15, 2001; 166(12): 7370 - 7380. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Shimizu, E. K. Thomas, M. Giedlin, and J. J. Mulé Enhancement of Tumor Lysate- and Peptide-pulsed Dendritic Cell-based Vaccines by the Addition of Foreign Helper Protein Cancer Res., March 1, 2001; 61(6): 2618 - 2624. [Abstract] [Full Text] |
||||
![]() |
T. Teshima, N. Mach, G. R. Hill, L. Pan, S. Gillessen, G. Dranoff, and J. L. M. Ferrara Tumor Cell Vaccine Elicits Potent Antitumor Immunity after Allogeneic T-Cell-depleted Bone Marrow Transplantation Cancer Res., January 1, 2001; 61(1): 162 - 171. [Abstract] [Full Text] |
||||
![]() |
A. McAllister, A. E. Arbetman, S. Mandl, C. Peña-Rossi, and R. Andino Recombinant Yellow Fever Viruses Are Effective Therapeutic Vaccines for Treatment of Murine Experimental Solid Tumors and Pulmonary Metastases J. Virol., October 1, 2000; 74(19): 9197 - 9205. [Abstract] [Full Text] |
||||
![]() |
M. J. Smyth, M. Taniguchi, and S. E. A. Street The Anti-Tumor Activity of IL-12: Mechanisms of Innate Immunity That Are Model and Dose Dependent J. Immunol., September 1, 2000; 165(5): 2665 - 2670. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. R. Surman, M. E. Dudley, W. W. Overwijk, and N. P. Restifo Cutting Edge: CD4+ T Cell Control of CD8+ T Cell Reactivity to a Model Tumor Antigen J. Immunol., January 15, 2000; 164(2): 562 - 565. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Dobrzanski, J. B. Reome, and R. W. Dutton Type 1 and Type 2 CD8+ Effector T Cell Subpopulations Promote Long-Term Tumor Immunity and Protection to Progressively Growing Tumor J. Immunol., January 15, 2000; 164(2): 916 - 925. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Winter, H.-M. Hu, W. J. Urba, and B. A. Fox Tumor Regression After Adoptive Transfer of Effector T Cells Is Independent of Perforin or Fas Ligand (APO-1L/CD95L) J. Immunol., October 15, 1999; 163(8): 4462 - 4472. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Ito, T. C. Back, A. N. Shakhov, R. H. Wiltrout, and S. A. Nedospasov Mice with a Targeted Mutation in Lymphotoxin-{alpha} Exhibit Enhanced Tumor Growth and Metastasis: Impaired NK Cell Development and Recruitment J. Immunol., September 1, 1999; 163(5): 2809 - 2815. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Wild, M. J. Grusby, R. Schirmbeck, and J. Reimann Priming MHC-I-Restricted Cytotoxic T Lymphocyte Responses to Exogenous Hepatitis B Surface Antigen Is CD4+ T Cell Dependent J. Immunol., August 15, 1999; 163(4): 1880 - 1887. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Dobrzanski, J. B. Reome, and R. W. Dutton Therapeutic Effects of Tumor-Reactive Type 1 and Type 2 CD8+ T Cell Subpopulations in Established Pulmonary Metastases J. Immunol., June 1, 1999; 162(11): 6671 - 6680. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. v. Leoprechting, P. van der Bruggen, H. L. Pahl, A. Aruffo, and J. C. Simon Stimulation of CD40 on Immunogenic Human Malignant Melanomas Augments Their Cytotoxic T Lymphocyte-mediated Lysis and Induces Apoptosis Cancer Res., March 1, 1999; 59(6): 1287 - 1294. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |